单磷酸阿糖腺苷离子导入治疗唇疱疹

Iontophoresis of vidarabine monophosphate for herpes orolabialis.

作者信息

Gangarosa L P, Hill J M, Thompson B L, Leggett C, Rissing J P

出版信息

J Infect Dis. 1986 Dec;154(6):930-4. doi: 10.1093/infdis/154.6.930.

DOI:10.1093/infdis/154.6.930

Abstract

The cutaneous application of antiviral agents was studied by iontophoresis, a process that increases penetration of most drugs 20- to 60-fold. Twenty-seven subjects with vesicular orolabial herpes were treated one time in a double-blind, placebo-controlled clinical study: nine received vidarabine monophosphate (ara-AMP), nine received acyclovir (ACV), and nine received NaCl. Ara-AMP-treated lesions yielded lower titers of virus after 24 hr compared with lesions treated with NaCl or ACV (P less than .05). Ara-AMP significantly decreased the duration of shedding of virus (P less than .05) and time to dry crust (P less than .05) compared with the other two agents. There was a trend toward decreased healing time after ara-AMP treatment.

摘要

通过离子导入法研究了抗病毒药物的皮肤应用，该方法可使大多数药物的渗透增加20至60倍。在一项双盲、安慰剂对照的临床研究中，对27名患有水疱性唇疱疹的受试者进行了一次治疗：9名接受单磷酸阿糖腺苷（ara-AMP），9名接受阿昔洛韦（ACV），9名接受氯化钠。与用氯化钠或阿昔洛韦治疗的皮损相比，ara-AMP治疗的皮损在24小时后病毒滴度更低（P<0.05）。与其他两种药物相比，ara-AMP显著缩短了病毒排出的持续时间（P<0.05）和结痂时间（P<0.05）。ara-AMP治疗后有愈合时间缩短的趋势。